This site is intended for health professionals only!

Published on 1 February 2007

Share this story:

AIs for advanced breast cancer

teaser

The use of third-generation aromatase inhibitors (AIs) in the treatment of advanced breast cancer in postmenopausal women shows survival benefits.

A Cochrane review compared AIs to other endocrine therapy in the treatment of advanced breast cancer in postmenopausal women, with 25 studies included in the main analysis (n=9,416).

The main findings were as follows. AIs were associated with a significant survival benefit over other endocrine therapies, and were not associated with any statistically significant difference in progression-free survival, clinical benefit and objective response. There were very limited data to compare one AI with a different AI, but these suggested an advantage for letrozole over anastrozole.

In the studies of AIs as first-line therapy (all versus tamoxifen), AIs were associated with statistically significant improvements in progression-free survival and clinical benefit, but not survival or objective response.

Finally, the use of an AI as second-line therapy showed a significant benefit in terms of overall survival but not for progression-free survival, clinical benefit or objective response.

 



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine